Seven Eight Capital’s CureVac CVAC Stock Holding History

Seven Eight Capital’s Portfolio CVAC Stock Details CVAC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-3,563	Closed	-$262K	–	588
2021 Q2	$262K	Buy	+3,563	New	+$356K	0.04%	516

Other funds holding CVAC

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Gates Foundation Seattle, Washington $43.5M AUM 14.19% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

DZ Bank Frankfurt Am Main, Germany $113B AUM 36.92% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Voloridge Investment Management Jupiter, Florida $25B AUM 28.08% 1-Year Est. Return

Seven Eight Capital's CVAC Position: Q3 2021 in Review

Seven Eight Capital sold out of CureVac (CVAC) in Q3 2021, closing a stake of 3,563 shares — an estimated $262K sold.

Seven Eight Capital first reported a position in CVAC in Q2 2021 and held it in 1 quarter. The position peaked at $262K in Q2 2021. 111 funds tracked by Wall St. Rank hold CVAC as of Q3 2021.

Seven Eight Capital reported no remaining CureVac position as of Q3 2021 after selling out during the quarter.
Seven Eight Capital sold 3,563 CureVac shares in Q3 2021, an estimated $262K.
Seven Eight Capital first reported a position in CureVac in Q2 2021 and held it in 1 quarter.
Seven Eight Capital's CureVac position peaked at $262K in Q2 2021.
111 funds tracked by Wall St. Rank held CureVac as of Q3 2021.

Based on Seven Eight Capital's 13F filing for Q3 2021, filed 15 Nov 2021.